N
Nir Peled
Researcher at Ben-Gurion University of the Negev
Publications - 273
Citations - 26175
Nir Peled is an academic researcher from Ben-Gurion University of the Negev. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 57, co-authored 244 publications receiving 18377 citations. Previous affiliations of Nir Peled include University of Colorado Boulder & Rabin Medical Center.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
TL;DR: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Kristel Vandormael,Antonio Riccio,J. Yang,M. Catherine Pietanza,Julie R. Brahmer +17 more
TL;DR: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolezumab as subsequent therapy.
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.